Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Endometrial Adenocarcinoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Endometrial Cancer (219)

Endometrial Cancer (219)

›

HER-2 expression	Endometrial Adenocarcinoma	HER-2 expression	Endometrial Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
No biomarker	Endometrial Adenocarcinoma	No biomarker	Endometrial Adenocarcinoma	ZN-c3 Sensitive: B - Late Trials ZN-c3 Sensitive : B	ZN-c3 Sensitive: B - Late Trials ZN-c3 Sensitive : B
HER-2 overexpression	Endometrial Adenocarcinoma	HER-2 overexpression	Endometrial Adenocarcinoma	trastuzumab Sensitive: C1 - Off-label trastuzumab Sensitive : C1	trastuzumab Sensitive: C1 - Off-label trastuzumab Sensitive : C1
HER-2 positive	Endometrial Adenocarcinoma	HER-2 positive	Endometrial Adenocarcinoma	trastuzumab Sensitive: C1 - Off-label trastuzumab Sensitive : C1	trastuzumab Sensitive: C1 - Off-label trastuzumab Sensitive : C1
MSI-H/dMMR	Endometrial Adenocarcinoma	MSI-H/dMMR	Endometrial Adenocarcinoma	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3
HER-2 positive	Endometrial Adenocarcinoma	HER-2 positive	Endometrial Adenocarcinoma	trastuzumab Sensitive: C3 – Early Trials trastuzumab Sensitive : C3	trastuzumab Sensitive: C3 – Early Trials trastuzumab Sensitive : C3
MSH2 deletion	Endometrial Adenocarcinoma	MSH2 deletion	Endometrial Adenocarcinoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
MLH1 deletion	Endometrial Adenocarcinoma	MLH1 deletion	Endometrial Adenocarcinoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
ARID1A mutation	Endometrial Adenocarcinoma	ARID1A mutation	Endometrial Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ER positive	Endometrial Adenocarcinoma	ER positive	Endometrial Adenocarcinoma	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3
ER positive	Endometrial Adenocarcinoma	ER positive	Endometrial Adenocarcinoma	letrozole Sensitive: C4 – Case Studies letrozole Sensitive : C4	letrozole Sensitive: C4 – Case Studies letrozole Sensitive : C4
MSH6 F1088fs	Endometrial Adenocarcinoma	MSH6 F1088fs	Endometrial Adenocarcinoma	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
HER-2 amplification	Endometrial Adenocarcinoma	HER-2 amplification	Endometrial Adenocarcinoma	lapatinib Sensitive: D – Preclinical lapatinib Sensitive : D	lapatinib Sensitive: D – Preclinical lapatinib Sensitive : D
HER-2 amplification	Endometrial Adenocarcinoma	HER-2 amplification	Endometrial Adenocarcinoma	trastuzumab + lapatinib Sensitive: D – Preclinical trastuzumab + lapatinib Sensitive : D	trastuzumab + lapatinib Sensitive: D – Preclinical trastuzumab + lapatinib Sensitive : D
HER-2 amplification	Endometrial Adenocarcinoma	HER-2 amplification	Endometrial Adenocarcinoma	afatinib Sensitive: D – Preclinical afatinib Sensitive : D	afatinib Sensitive: D – Preclinical afatinib Sensitive : D